Abstract
Ivabradine, the first representative of a new class of exclusive heart rate-reducing agents, selectively inhibits the I(f) current in the sinoatrial node. The direct electrophysiological consequence of this inhibition is a reduction in the slope of the diastolic depolarisation curve and a decrease in heart rate. Pharmacological inhibition of the I(f) current with ivabradine has been shown to preserve coronary vasodilatation upon exercise, i.e., myocardial perfusion, with no negative inotropic effects and maintenance of cardiac contractility. Ivabradine protects the myocardium during ischaemia, improves left ventricular function in congestive heart failure, and reduces remodelling subsequent to myocardial infarction. Pure heart rate reduction by specific and selective I(f) inhibition decreases oxygen demand, improves myocardial energetics and improves perfusion of the ischaemic myocardium. We can expect distinct clinical benefits from long-term heart rate reduction in patients with chronic ischaemic disease.
Citations
Feb 8, 2007·Cardiovascular Drugs and Therapy·Houman Ashrafian, Michael P Frenneaux
Apr 9, 2009·Journal of Bioenergetics and Biomembranes·H Lemieux, C L Hoppel
Jan 24, 2009·Advances in Therapy·Graziano RiccioniNicolantonio D'Orazio
Sep 13, 2012·Heart Failure Reviews·Moritz OsterholtTorsten Doenst
Dec 3, 2014·International Journal of Cardiology·Katrine H SlagsvoldAlexander Wahba
Aug 30, 2011·The International Journal of Biochemistry & Cell Biology·Hélène LemieuxErich Gnaiger
Nov 19, 2011·British Journal of Pharmacology·Martina Del LungoElisabetta Cerbai
Sep 29, 2009·American Heart Journal·Ralf KösterUNKNOWN REDUCTION Study Group
May 31, 2012·TheScientificWorldJournal·Jacek OwczarekDaria Orszulak-Michalak
Jul 11, 2016·International Journal of Cardiology·Song-Young ParkRussell S Richardson
Oct 13, 2009·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Alexandre SarreEric Raddatz
Nov 9, 2016·Case Reports in Neurological Medicine·Giuliano Ohde DalledoneRosana Herminia Scola
Nov 8, 2011·Kidney & Blood Pressure Research·Ali BeyturAhmet Acet
Feb 1, 2011·Therapeutic Advances in Drug Safety·Gordon F RushworthStephen J Leslie
Dec 29, 2013·Circulation Research·Katrine Hordnes SlagsvoldAlexander Wahba
Nov 27, 2008·Journal of Cardiovascular Pharmacology·Fanny VaillantPhilippe Chevalier
Feb 13, 2009·Expert Review of Cardiovascular Therapy·Graziano Riccioni
Feb 23, 2012·Human & Experimental Toxicology·M C ColakA Acet
Feb 26, 2013·British Journal of Haematology·Andranik A Aprikyan, Zaza Khuchua
May 22, 2019·Scientific Reports·Karima Ait-AissaAndreas M Beyer
Dec 6, 2007·Drugs·Alain Berdeaux
Nov 29, 2013·American Journal of Physiology. Heart and Circulatory Physiology·Dingding XiongZaza Khuchua
Jul 17, 2015·Bioscience Reports·Brittany BeauchampMary-Ellen Harper
Oct 23, 2018·Medicina·Marlon E Cerf
Nov 21, 2019·Cells·Miroslav FerkoMagdaléna Jašová
Jun 30, 2019·Life Sciences·Severina Cássia Andrade SilvaClaudia Jacques Lagranha
Dec 17, 2009·Trends in Cardiovascular Medicine·Jan-Christian ReilMichael Böhm